Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial.
BACKGROUND
To provide broader protection against pneumococcal disease, new vaccines containing conserved Streptococcus pneumoniae proteins are being developed. This study assessed the safety, reactogenicity and immunogenicity of four formulations containing pneumococcal proteins pneumolysin toxoid (dPly) and histidine triad protein (PhtD) in toddlers.


METHODS
In this phase II, multicenter, observer-blind study (www.clinicaltrials.gov: NCT00985751) conducted in the Czech Republic, toddlers (12-23 months) were randomized (1:1:1:1:1) to receive one of four investigational vaccine formulations (10 or 30μg each of dPly and PhtD, alone or in combination with polysaccharide conjugates from the pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine [PHiD-CV]), or the licensed PHiD-CV, in a 2-dose primary series plus booster at study months 0, 2 and 6. Solicited local and general symptoms were recorded within seven days post-vaccination, unsolicited symptoms within 31 days post-vaccination, and serious adverse events (SAEs) during the entire study period. Antibody concentrations against the vaccine components were measured pre-vaccination, one month post-dose 2, pre- and one month post-booster.


RESULTS
257 toddlers were enrolled and vaccinated. Percentages of solicited local and general symptoms following the different investigational formulations were generally within the same ranges as for PHiD-CV. After each dose, grade 3 fever (>40.0°C, rectal measurement) was reported for maximum one toddler in each group with no differences between investigational formulations and PHiD-CV during primary vaccination. 23 SAEs were reported for 17 toddlers, with distribution balanced between all groups except the group receiving 30 μg dPly/PhtD with PHiD-CV-conjugates (no SAEs reported). None of the SAEs were considered to be vaccine-related. For all pneumococcal protein-containing formulations, anti-PhtD and anti-Ply antibody geometric mean concentrations increased from pre-vaccination to post-dose 2 and from pre- to post-booster vaccination.


CONCLUSIONS
All investigational vaccine formulations were well-tolerated and immunogenic when administered to toddlers as a 2-dose primary vaccination followed by a booster dose.
University Hospital, Hradec Kralove, Czech Republic. Electronic address: prymula@fnhk.cz.
Roman
R
Prymula
University Hospital, Pilsen, Czech Republic. Electronic address: pazdiora@fnplzen.cz.
Petr
P
Pazdiora
GlaxoSmithKline Vaccines, Wavre, Belgium. Electronic address: Magali.x.traskine@gsk.com.
Magali
M
Traskine
GlaxoSmithKline Vaccines, Wavre, Belgium. Electronic address: jrueggeberg@doctors.org.uk.
Jens U
JU
Rüggeberg
GlaxoSmithKline Vaccines, Wavre, Belgium. Electronic address: dorota.d.borys@gsk.com.
Dorota
D
Borys
D000907:Antibodies, Bacterial / Q000097:blood; D001426:Bacterial Proteins / Q000276:immunology; D018153:Czech Republic; D015507:Drugs, Investigational; D005260:Female; D006801:Humans; D006867:Hydrolases / Q000276:immunology*; D007117:Immunization, Secondary; D007223:Infant; D008297:Male; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D013301:Streptolysins / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D015507:Drugs, Investigational; D022242:Pneumococcal Vaccines; D013301:Streptolysins; D018074:Vaccines, Conjugate; C097552:histidine triad protein; C032290:plY protein, Streptococcus pneumoniae; D006867:Hydrolases
Immunogenicity; PhtD; Pneumococcal proteins; Safety; Toddler vaccination; dPly